How long can I take ritexitinib for? What is the best course of treatment?

Ritlecitinib is a selective JAK3 and TEC family kinase inhibitor that is currently approved by the FDA for the treatment of moderate to severe alopecia areata in patients 12 years and older. According to currently published clinical research data, including trials such as ALLEGRO and ALLEGRO-LT, patients can observe significant hair regeneration effects as early as 12 weeks during treatment with ritexitinib, but maintenance effects usually appear after 24 to 36 weeks. Research shows that among patients who continued to take it for 48 weeks, the proportion of patients who achieved SALT ≤ 20 (alopecia areata area index) significantly increased, indicating that long-term medication is of great value in maintaining efficacy.

There is currently no unified standard stipulating the maximum length of time that ritexitinib can be taken, but in multiple clinical trials, some patients have completed continuous use for more than one year, and the safety is good, indicating that the drug can be used for long-term maintenance treatment, provided that the patient tolerates the drug well and the efficacy is sustained. Doctors usually adjust the course of medication based on changes in the patient's condition, severity of hair loss, and therapeutic response. Some studies have pointed out that after significant hair regrowth, some patients maintain the therapeutic effect within a few months of stopping the drug, but a certain proportion of patients experience hair loss again after stopping the drug. Therefore, individual decision-making is required whether to take it for a long time.

The best course of treatment should be chosen based on24 weeks as the basic observation period. If the patient does not show obvious hair regrowth during this period, the doctor may evaluate whether to continue the treatment; if there is obvious effect, the treatment can be extended to 48 weeks or even longer to consolidate the effect. In short, the usage cycle of ritexitinib needs to be dynamically evaluated based on patient response, persistence of efficacy and control of adverse reactions. Do not extend or discontinue the drug on your own to ensure both treatment safety and effectiveness.

Reference materials:https://www.litfulo.com/